Completed Transactions

Completed Transactions > Healthcare > Evolution Research Group Acquires Endeavor Clinical Trials

Evolution Research Group Acquires Endeavor Clinical Trials

Endeavor Clinical Trials

Date

Jul 2017

Region

Texas

Generational Capital Markets, Inc., Member FINRA/SIPC and a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, Endeavor Clinical Trials P.A. (ECT), to Evolution Research Group, LLC (ERG). The acquisition closed July 31, 2017.

Endeavor Clinical Trials, based in San Antonio, Texas, has 20-plus years of experience conducting more than 185 clinical trials. It specializes in post-operative pain, neuropathic pain, podiatry, and vaccine research, among others. ECT’s clinical operations team of more than 45 is led by Dr. Richard A. Pollak, who will remain with the company and continue to act as Principal Investigator. Dr. Pollak is a key opinion leader in podiatry and is board-certified by the American Board of Foot and Ankle Surgery.

“The decision to join the ERG portfolio made so much sense given their experience, expertise and reputation in the industry,” said Dr. Pollak. “It was very important to me that we select a group that values quality as much as we do.” 

Evolution Research Group, headquartered in Watchung, New Jersey, is the largest, privately held clinical research site company in the United States. The acquisition of ECT grows ERG to eight portfolio research units. Denise Roberts, ERG Executive Director of Clinical Operations and Site Development and a leader in the field of analgesic research, will be leading the clinical trial operations at Endeavor Clinical Trials.

“ECT's excellent reputation in the industry, and more specifically in the field of postoperative pain research, adds tremendous value to ERG's established leadership position in the field of neuroscience research,” said Lori Wright, CEO of Evolution Research Group. “The postoperative pain expertise that Richard, Denise and the ECT team bring to ERG nicely complements our psychiatry, neurology, addiction, sleep and early phase capabilities, and broadens our service offering to the industry."

Generational Capital Markets Managing Directors Tom Staszak and Chris Gain successfully closed the deal.

“ECT has a well established and industry recognized area of expertise in the fast-growing pain study industry,” said Staszak. “By joining with ERG, ECT is well positioned for additional growth.”

Instant
Contact